Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Intellia Therapeutics to post earnings of ($1.21) per share for the quarter.
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) last announced its earnings results on Thursday, May 9th. The company reported ($1.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.35) by $0.29. The firm had revenue of $28.94 million for the quarter, compared to the consensus estimate of $15.60 million. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Intellia Therapeutics Stock Down 7.3 %
Intellia Therapeutics stock traded down $1.83 during trading hours on Friday, reaching $23.31. 114,221 shares of the company’s stock were exchanged, compared to its average volume of 1,556,908. The firm has a market capitalization of $2.25 billion, a PE ratio of -4.54 and a beta of 1.81. The firm’s 50 day simple moving average is $24.33 and its 200 day simple moving average is $25.44. Intellia Therapeutics has a twelve month low of $19.37 and a twelve month high of $40.98.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on Intellia Therapeutics
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Featured Stories
- Five stocks we like better than Intellia Therapeutics
- Stock Sentiment Analysis: How it Works
- Amazon Stock is Primed to Rebound Strongly After AI Bubble Bursts
- What is the Nikkei 225 index?
- Shell Stock: Oil & Gas Giant Committed to Buybacks and Dividends
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Chevron Stock Dips as Earnings Miss Highlights Merger Uncertainty
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.